Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02517281

Acronym

SKINTARGET

Enrollment

141

Registered

2015-08-07

Start date

2011-07-12

Completion date

2022-06-22

Last updated

2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

The aim of the study is to do a descriptive analysis of the cutaneous toxicity observed in patients treated using targeted therapies in order to have a better understanding of the skin pathophysiology.

Interventions

PROCEDUREBiopsy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with cancer beginning a targeted therapy * Patients able to follow the protocol * Age \>/= 18 years old * Signed inform consent

Exclusion criteria

* Patient unable to follow the protocol, having a non cooperative behavior or unable to come to follow up visits or unable to complete the study * Pregnant or breastfeeding woman

Design outcomes

Primary

Measure	Time frame	Description
Number of clinical secondary effects bind to targeted therapies	Every 28 days up to 5 years	Dermatological exam including questionnaire, clinical examination and photographies

Countries

France

Contacts

STUDY_CHAIRCaroline Robert, MD

Gustave Roussy, Cancer Campus, Grand Paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026